2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 267

Diffuse Idiopathic Skeletal Hyperostosis: Can We Identify Different Clinicoradiological Patterns?
Abstract Number: 268

Effect of Abatacept Treatment on T Cells in Muscle Tissue and Peripheral Blood in Polymyositis and Dermatomyositis Patients
Abstract Number: 269

The Immunoproteasomes Are Essential for Maintaining Myokine Production and MHC Class I Expression in Idiopathic Inflammatory Myopathies
Abstract Number: 270

Retinoic Acid-Inducible Gene-I Increased in Peripheral CD3+T Lymphocytes of Patients with Dermatomyositis
Abstract Number: 271

Impaired Satellite Cell Activation and Myofiber Transition during Skeletal Muscle Regeneration in Patients with Polymyositis and Dermatomyositis
Abstract Number: 272

Interferon Chemokine Score and Other Cytokine Measures Predict Changes in Disease Activity in Patients with Juvenile and Adult Dermatomyositis
Abstract Number: 273

Juvenile Dermatomyositis Patient-Derived Induced Pluripotent Stem Cells Do Not Retain Disease Expression Signatures
Abstract Number: 274

Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.
Abstract Number: 275

In Vitro Activation of Type I Interferon Pathway Reproduces the Characteristics Damages Observed in Dermatomyositis Patients
Abstract Number: 276

Histological Study on the Expression of Transcriptional Intermediary Factor 1 (TIF1) in the Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 277

Abnormal Composition of Circulating T and B Cells in Patients with Polymyositis and Dermatomyositis Is More Biased in Those with Interstitial Lung Diseases
Abstract Number: 278

Expression of Anti-Microbial Peptide LL-37 Correlates to the Activation of Type I Interferon Pathway in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 279

Increased Heat Shock Protein 90 in Muscle Tissue and Plasma in Idiopathic Inflammatory Myopathies Correlates with Disease Activity and Skeletal Muscle Involvement
Abstract Number: 280

Increased Expression of TIF-1 Gamma in Duodenal Adenocarcinoma from a Patient with p155/140 Dermatomyositis: A Causal Relationship?
Abstract Number: 281

Characterization of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].